Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.

CONCLUSION: Aflibercept results in improvement in CMT in non-responders to ranibizumab and bevacizumab as long as therapy is given continuously and can therefore be an alternative therapy. PMID: 27550436 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27550436?dopt=Abstract

Source: Wiener Klinische Wochenschrift - August 21, 2016 Category: Journals (General) Authors: Maksys S, Richter-Müksch S, Weingessel B, Vécsei-Marlovits PV Tags: Wien Klin Wochenschr Source Type: research